UNSPSC 51321811: Ronifibrate

This classification denotes an anti-lipidemic agent with the molecular formula C19H20ClNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W86I18X716, chemically known as 3-pyridinecarboxylic acid, 3-(2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy)propyl ester but generally known as ronifibrate, which bears US NIH Compound Identifier 68671. European Medicines Agency schedules Ronifibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10378MIG.

UNSPSC 51321811 Ronifibrate is a Commodity code covering pharmaceutical active ingredients and finished medications purchased by state and local health agencies, fire rescue services, and health benefit programs. State and local governments buy these products primarily for emergency medical services, pharmacy benefit programs, and institutional healthcare delivery. Recent solicitations show demand for advanced life support medications supplied to emergency responders, generic pharmaceuticals distributed through state health benefit programs and cooperative purchasing arrangements, and direct-to-manufacturer prescription fulfillment models for state employee health plans. The mix of issuing bodies spans city fire and rescue departments, state health agencies, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions.

Activity under this code concentrates in Texas, Minnesota, and Florida. The City of Tampa's Purchasing Department solicited sealed bids (No. 26P00188) for Advanced Life Support Medications—Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue—with a response deadline of April 8, 2026, and an estimated contract value of $40,000, structured as a one-year term with options to renew for two additional years. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products to be distributed across member state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and products effective July 1, 2026. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs for state employee health plans, signaling exploratory procurement activity before formal RFP release. Tampa's solicitation includes a 5 percent SLBE bid discount, while MMCAP reserves multi-award authority based on therapeutic considerations and member-specific needs.